Here, we argue that PARKIN PD patients and other PD patients (e.g. PINK1) with predominant nigral pathology without active synucleinopathy may be ideal candidates for a cell replacement therapy for two major reasons (a) their grafts are unlikely to be affected by Lewy pathology, and (b) non‐nigral systems will remain unaffected as this is the normal course for this subtype of PD. This evidence concerns the gene PRKN and synucleinopathy.